Necrotizing myopathy (NM) is a rare but serious disease characterized by the progressive destruction of muscle fibers. This syndrome is usually associated with an autoimmune process, in which the immune system mistakenly attacks the body's own tissues. NM can manifest itself in varying degrees of severity, from mild muscle weakness to complete muscle destruction, which leads to significant loss of functionality. One of the key features of this disease is that it can occur against the background of viral infections or after vaccination. Clinically, it can manifest itself suddenly, often in young and middle-aged people, and requires a rapid and competent approach to diagnosis and treatment.
History of the disease and interesting historical facts
Necrotizing myopathy was first described in the medical literature in the mid-20th century. One of the first reports of this condition was a case in 1960, in which patients with significant muscle weakness were examined for myopathological changes. In the 1980s, more detailed studies began that shed light on the molecular mechanisms of the disease and its relationship with autoimmune disorders. It is also worth noting that the initial phase of NM research often focused on its relationship with other myopathies, such as polymyositis and dermatomyositis, which led to misunderstandings in the understanding of the pathogenesis.
Epidemiology
According to various studies, the prevalence of necrotizing myopathy is estimated at approximately 1-8 cases per 100,000 population. This disease is more common in adults, especially aged 40-60 years, but cases of diagnosis in childhood also occur. Gender differences in cases are found in favor of women, in whom the disease occurs more often than in men, on average, the ratio is 3:1. In recent decades, an increase in cases has been observed, which may be due to both improved diagnostics and awareness of NM, and an increase in the number of cases associated with autoimmune disorders.
Genetic predisposition to this disease
Genetic predisposition to necrotizing myopathy is still being studied. Among the genes involved are MARVELD1, DYSF, and TTN, which are associated with various forms of myopathy. Mutations in these genes may predispose to the development of NM or contribute to its more severe course. Studies show that individuals with relatives suffering from autoimmune diseases may have a significantly higher risk of developing NM. It is important to consider that a weakened immune system caused by a genetic predisposition may increase the likelihood of relapses of the disease.
Risk factors for the development of this disease
Among the risk factors for the development of necrotizing myopathy, both physical and chemical components can be identified that can trigger the onset of the disease. These include:
- Viral infections (eg, infections caused by the Epstein-Barr virus or influenza).
- Some vaccines may cause autoimmune reactions.
- Thyroid disease (hypothyroidism).
- Exposure to certain toxins or chemicals, such as some harsh medications (eg, statins).
Chronic stress and other autoimmune disorders may also serve as factors contributing to the development of NM.
Diagnosis of this disease
Diagnosis of necrotizing myopathy requires a comprehensive approach and includes several stages aimed at identifying key symptoms and confirming the disease:
- Main symptoms: muscle weakness, rapid fatigue, muscle soreness and atrophy, as well as increased levels of creatine phosphokinase in the blood.
- Laboratory tests: biochemical blood test to assess the level of muscle enzymes, serological markers (anti-Jo-1, anti-SRP) for the diagnosis of autoimmune nature.
- Radiological examinations: Magnetic resonance imaging (MRI) to visualize muscle changes and assess the degree of involvement.
- Other types of disease diagnostics: electromyography (EMG), which allows assessing the electrical activity of muscles.
- Differential diagnosis: It is necessary to exclude other myopathies, such as polymyositis, myogenic disorders or dystrophies, which requires additional tests and specialist consultations.
Treatment
Treatment of necrotizing myopathy requires a multi-stage and individualized approach. The main methods include:
- General treatment: ensuring rest, using physical therapy to maintain function and improve muscle tone.
- Pharmacological treatment: corticosteroids and immunosuppressants (eg, methotrexate, azathioprine) to suppress the immune response.
- Surgical treatment: In some cases, surgery may be required to correct deformities caused by diseases.
- Other types of treatment: the use of biological therapies, such as anti-IL-6 drugs, which may be effective in cases of resistance to traditional treatments.
List of medications used to treat this disease
- Corticosteroids (Prednisolone, Dexamethasone).
- Immunosuppressants (Methotrexate, Azathioprine, Cyclosporine).
- Biological drugs (Tocilizumab, Rituximab).
- Muscle relaxants to relieve symptoms and reduce muscle tension.
Disease monitoring
Monitoring of patients with necrotizing myopathy is an important aspect of disease management. It includes:
- Control stages: regular check-ups with a rheumatologist, biochemical blood tests for muscle enzyme levels and assessment of muscle function.
- Forecast: With early initiation of treatment and adequate therapy, the prognosis is often favorable, but a chronic course with periods of exacerbation is possible.
- Complications: It is possible to develop post-operative shoulder syndrome, and dysfunction of other organs, including the respiratory and cardiovascular systems.
Age-related features of the disease
Necrotizing myopathy can manifest itself in different age groups, which determines its clinical course and approaches to treatment. In children, the disease can develop rapidly, often manifesting itself in the form of acute myositis, and requiring more aggressive treatment. In elderly patients, NM usually develops against the background of other chronic diseases, which can complicate diagnosis and therapy, as well as reduce the overall quality of life.
Questions and Answers
- What is necrotizing myopathy? Necrotizing myopathy is an autoimmune disease that involves the destruction of muscle fibers, causing muscle weakness and atrophy.
- What are the main symptoms of this disease? The main symptoms include muscle weakness, soreness, fatigue and decreased muscle function.
- How is necrotizing myopathy diagnosed? Diagnosis includes laboratory tests, EMG, MRI and serologic tests to detect autoimmune markers.
- What are the main treatment methods for the disease? Treatment includes corticosteroids, immunosuppressants, physical therapy, and in some cases surgery.
- What is the likelihood of recurrence of the disease? Relapse may occur if the patient's condition is not closely monitored and adequate treatment is not provided.
In conclusion, necrotizing myopathy is a serious condition that requires early diagnosis and effective treatment to prevent severe consequences and maintain body function.
